477 related articles for article (PubMed ID: 27746282)
21. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
22. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
23. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
24. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.
Pernthaler B; Kulnik R; Gstettner C; Salamon S; Aigner RM; Kvaternik H
Clin Nucl Med; 2019 Oct; 44(10):e566-e573. PubMed ID: 31283605
[TBL] [Abstract][Full Text] [Related]
25. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Schreibmann E; Schuster DM; Rossi PJ; Shelton J; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):206-13. PubMed ID: 27511856
[TBL] [Abstract][Full Text] [Related]
26. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with
Pienta KJ; Gorin MA; Rowe SP; Carroll PR; Pouliot F; Probst S; Saperstein L; Preston MA; Alva AS; Patnaik A; Durack JC; Stambler N; Lin T; Jensen J; Wong V; Siegel BA; Morris MJ
J Urol; 2021 Jul; 206(1):52-61. PubMed ID: 33634707
[TBL] [Abstract][Full Text] [Related]
27.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
28. Impact of
Andriole GL; Scarsbrook AF; Savir-Baruch B;
Urol Oncol; 2023 Jun; 41(6):293.e1-293.e7. PubMed ID: 37121865
[TBL] [Abstract][Full Text] [Related]
29. The role of
Kim SJ; Lee SW
Clin Radiol; 2019 Nov; 74(11):886-892. PubMed ID: 31358294
[TBL] [Abstract][Full Text] [Related]
30. Prostate Specific Membrane Antigen Targeted
Gorin MA; Rowe SP; Patel HD; Vidal I; Mana-Ay M; Javadi MS; Solnes LB; Ross AE; Schaeffer EM; Bivalacqua TJ; Partin AW; Pienta KJ; Szabo Z; De Marzo AM; Pomper MG; Allaf ME
J Urol; 2018 Jan; 199(1):126-132. PubMed ID: 28736318
[TBL] [Abstract][Full Text] [Related]
31.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
32. A bicentric retrospective analysis of clinical utility of
Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
[TBL] [Abstract][Full Text] [Related]
33. A review discussing fluciclovine (
Zanoni L; Bossert I; Matti A; Schiavina R; Pultrone C; Fanti S; Nanni C
Future Oncol; 2018 May; 14(11):1101-1115. PubMed ID: 29359581
[TBL] [Abstract][Full Text] [Related]
34. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
[TBL] [Abstract][Full Text] [Related]
35. Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences.
Hwang L; Paluch J; Jadvar H; England JR; Desai B; Ballas LK
Clin Nucl Med; 2020 Sep; 45(9):668-671. PubMed ID: 32520496
[TBL] [Abstract][Full Text] [Related]
36. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on
Markowski MC; Sedhom R; Fu W; Gray JCR; Eisenberger MA; Pomper MG; Pienta KJ; Gorin MA; Rowe SP
J Urol; 2020 Sep; 204(3):496-502. PubMed ID: 32250727
[TBL] [Abstract][Full Text] [Related]
37. Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer.
Farkas AB; Green ED; Thaggard AL; Vijayakumar V; Henegan JC; Lirette ST; Nittala MR; Vijayakumar S
South Med J; 2021 Nov; 114(11):703-707. PubMed ID: 34729614
[TBL] [Abstract][Full Text] [Related]
38. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
39. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
[TBL] [Abstract][Full Text] [Related]
40. [
Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
